NCT03346772 Study of Immune Responses to Influenza Vaccination
| NCT ID | NCT03346772 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Pennsylvania |
| Condition | Influenza Vaccination |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2017-10-20 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 75 participants in total. It began in 2017-10-20 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.
Eligibility Criteria
Inclusion Criteria: * Community-dwelling adults able to provide consent who need influenza vaccination for standard of care Exclusion Criteria: * febrile illness at time of vaccination * active malignancy * use of immunosuppressing medications * blood donation in the past 60 days * influenza vaccinated during the preceding 6 months * allergic reactions to influenza vaccination
Contact & Investigator
E.John Wherry, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT03346772 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Influenza Vaccination. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03346772 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03346772 currently recruiting?
Yes, NCT03346772 is actively recruiting participants. Contact the research team at sokratis.apostolidis@pennmedicine.upenn.edu for enrollment information.
Where is the NCT03346772 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT03346772 clinical trial?
NCT03346772 is sponsored by University of Pennsylvania. The principal investigator is E.John Wherry, PhD at University of Pennsylvania. The trial plans to enroll 75 participants.